Table 3.

Univariate and multivariate analyses of risk factors and OS in the training cohort.

Variables	HR (95% CI)	P-Value
Univariate analyses
Age (years) (>60 vs. ≤ 60)	1.346 (0.973–1.863)	0.073
Race
White vs. Other	0.532 (0.216–1.306)	0.168
Asian vs. Other	0.779 (0.186–3.268)	0.733
Black or African American vs. Other	0.940 (0.320–2.759)	0.910
Anatomic subdivision (Bilateral vs. Unilateral)	1.243 (0.831–1.859)	0.290
Neoplasm histologic grade (G3–4 vs. G1–2)	1.092 (0.692–1.724)	0.705
Clinical stage (III and IV vs. I and II)	2.298 (0.849–6.221)	0.102
Chemotherapy (No vs. Yes)	2.351 (1.367–4.044)	0.002
Hormone therapy (Yes vs. No)	1.065 (0.633–1.792)	0.812
Targeted molecular therapy (Yes vs. No)	0.729 (0.394–1.348)	0.314
Immunotherapy (Yes vs. No)	0.812 (0.332–1.988)	0.649
Risk score (high-risk vs. low-risk)	2.314 (1.652–3.243)	<0.001
Multivariate analyses
Chemotherapy (No vs. Yes)	2.058 (1.195–3.542)	0.009
Risk score (high-risk vs. low-risk)	2.242 (1.598–3.145)	<0.001

HR, hazard ratio; CI, confidence interval; OS, overall survival; AJCC, American Joint Committee on Cancer.